Thomas Rossi, Ph.D. is currently serving as CEO of Venthera, Inc. He is an experienced entrepreneur and drug development professional focused on development stage companies in the dermal and women's healthcare domains. Past CEO roles include Agile Therapeutics (currently marketing Twirla - a transdermal female contraceptive patch) and SansRosa (originator of Mirvaso(R) for the treatment of erythema of rosacea). Previously, Dr. Rossi was on the management board of The R.W. Johnson Pharmaceutical Research Institute, the prescription drug development arm of Johnson & Johnson, where he led all aspects of non-clinical development. He received a Ph.D. in Chemistry from Texas A&M University in 1980, and is active in numerous professional societies and civic organizations.